Amgen stock trades near 52-week high as guidance for 2026 rises
Published on 09/04/2026 at 08:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Amgen stock (ISIN US0311621009) is trading close to its 52-week high in early September 2026, with recent quotes around USD 441.56 as of September 3, 2026 according to market data compiled by Investing.com, leaving the shares about USD 5.47 below a 52-week high of USD 447.03 on Nasdaq.
Stock hovers just below yearly peak
Market data summarized by Investing.com indicate that Amgen’s share price recently stood at about USD 441.56, while the 52-week range was roughly USD 269.77 to USD 447.03 as of September 3, 2026, highlighting a strong recovery from the lower end of that corridor over the past year.
The same compiled overview points to a market capitalization near USD 239.41 billion for Amgen around September 3, 2026, underscoring the company’s status as a heavyweight in the global biotechnology sector and a significant component of the S&P 500 health care segment.
Q2 2026 growth underpins stronger outlook
According to a recent summary of Amgen’s latest figures cited by an overview built on Simplify data and reflected in an ad-hoc-news company profile, the group reported revenue of about USD 10.05 billion in Q2 2026, representing growth of roughly 9 percent compared with the same quarter a year earlier.
The same Q2 2026 snapshot notes that Amgen’s revenue expansion is broad-based across key therapeutic areas, with core products and newer launches contributing to the mid-single-digit to high-single-digit percentage growth that adds up to the roughly 9 percent year-on-year increase to USD 10.05 billion in the quarter.
On the back of this Q2 2026 performance, Amgen raised its full-year 2026 revenue guidance, with one Simplify-based summary pointing to a new range that extends up to approximately USD 39.4 billion, compared with a previously lower band, signaling management’s confidence in continued momentum over the remainder of the year.
Guidance for 2026 sharpened for revenue and EPS
A detailed analysis of Amgen’s latest outlook compiled by Zacks and echoed by Yahoo Finance reports that the company has lifted its total revenue guidance for 2026 to a range of USD 38.2 billion to USD 39.4 billion, up from a prior expectation of USD 37.1 billion to USD 38.5 billion, marking an increase of about USD 1.1 billion at the top end.
The same guidance update shows that adjusted earnings per share (EPS) for fiscal year 2026 are now projected in a corridor of USD 22.30 to USD 23.50, compared with a previous range of USD 21.70 to USD 23.10, implying that the upper end of the EPS outlook has risen by USD 0.40 while the lower bound is up by USD 0.60 as management tightens expectations.
In addition, Amgen’s adjusted operating margin for 2026 is targeted at around 45 percent to 46 percent, according to the Yahoo Finance summary of company statements, alongside an expected adjusted tax rate of 15.0 percent to 16.5 percent, capital expenditures of approximately USD 2.6 billion and share repurchases capped at no more than USD 3 billion for the year.
More on Amgen stock and recent figures
Investors who want to follow Amgen’s latest filings, guidance changes and market reactions can find additional headlines and figures in the dedicated topic section for the ISIN US0311621009 and via the company’s investor relations resources.
Representative product: Enbrel and immunology portfolio
Among Amgen’s long-standing revenue drivers is Enbrel, a biologic therapy for autoimmune conditions such as rheumatoid arthritis, which has historically contributed several billion dollars in annual sales and remains a key part of the company’s immunology portfolio alongside newer agents that help stabilize overall revenue despite competitive pressures.
Stock valuation and recent price level
Analyst commentary compiled by Investing.com notes that Amgen shares around USD 441.56 are only about USD 5.47, or roughly 1.2 percent, below the recorded 52-week high of USD 447.03, highlighting how the current valuation already prices in much of the improved 2026 guidance even as some fair value models still see limited further upside.
Amgen stock snapshot
- Company: Amgen Inc.
- ISIN: US0311621009
- Ticker: AMGN
- Trading venue: NASDAQ
- Price (as of September 3, 2026): 441.56 USD
- Market capitalization: 239.41 billion USD (as of September 3, 2026)
- Sector / Industry: Biotechnology / Pharmaceuticals
- Index membership: S&P 500
